Sale!

Research paper on Multiple Myeloma Post-Autologous (ASCT) Stem Cell Therapy

Original price was: ₹21,240.00.Current price is: ₹10,620.00. inc. GST

Research paper on Multiple Myeloma Post-Autologous (ASCT) Stem Cell Therapy

1 in stock

Description

Title: Multiple Myeloma Post-Autologous (ASCT) Stem Cell Therapy

Abstract: In patients with multiple myeloma who are transplant-eligible, autologous stem cell transplantation (ASCT) is the standard of care and is linked to a notable improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, with a median PFS of about 36 months, the majority of patients eventually relapse. Relapses are more difficult to treat, and the prognosis gets worse with each one. The ultimate goal of first-line therapy is to achieve and maintain “best response” to initial therapy, and sustained CR is a potent substitute for prolonged survival, particularly in high-risk multiple myeloma. In order to deepen and/or maintain the response achieved by induction and ASCT, ASCT is frequently followed by a consolidation/maintenance phase. Thalidomide, lenalidomide, and bortezomib are examples of novel agents that have been used alone or in combination. The use of thalidomide has been linked to a significant improvement in PFS and EFS, but with significant side effects. Data on lenalidomide maintenance following ASCT are encouraging, but it is still unknown how long maintenance should last. Use of bortezomib has been linked to better outcomes, primarily in patients with high-risk myeloma. The best results have been achieved with regimens that combine an immunomodulatory drug (such as thalidomide or lenalidomide) with a proteasome inhibitor (such as bortezomib). The best research on post-ASCT strategies for multiple myeloma is reviewed in this review article.

Paper Quality: SCOPUS / Web of Science Level Research Paper

Subject: Medicine

Sub Category: Hematology

Writer Experience: 20+ Years

Plagiarism Report: Turnitin Plagiarism Report will be less than 10%

Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.

What will I get after the purchase?

A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.

In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.